Physicians at the University of Illinois Hospital & Health Sciences System have cured 12 adult patients of sickle cell disease using a unique procedure for stem cell transplantation from healthy, tissue-matched siblings.
The transplants were the first to be performed outside of the National Institutes of Health campus in Maryland, where the procedure was developed. Physicians there have treated 30 patients, with an 87 percent success rate. The results of the phase I/II clinical trial at UI Health, in which 92 percent of treated patients were cured, are published online in the journal Biology of Blood & Marrow Transplantation.
The new technique eliminates the need for chemotherapy to prepare the patient to receive the transplanted cells and offers the prospect of cure for tens of thousands of adults suffering from sickle cell disease.
About 90 percent of the approximately 450 patients who have received stem cell transplants for sickle cell disease have been children. Chemotherapy has been considered too risky for adult patients, who are often more weakened than children by the disease.
“Adults with sickle cell disease are now living on average until about age 50 with blood transfusions and drugs to help with pain crises, but their quality of life can be very low,” says Dr. Damiano Rondelli, chief of hematology/oncology and director of the blood and marrow transplant program at UI Health, and corresponding author on the paper.
“Now, with this chemotherapy-free transplant, we are curing adults with sickle cell disease, and we see that their quality of life improves vastly within just one month of the transplant,” said Rondelli, who is also the Michael Reese Professor of Hematology in the UIC College of Medicine. “They are able to go back to school, go back to work, and can experience life without pain.”
Sickle cell disease is inherited. It primarily affects people of African descent, including about one in every 500 African Americans born in the U.S. The defect causes the oxygen-carrying red blood cells to be crescent shaped, like a sickle. The misshapen cells deliver less oxygen to the body’s tissues, causing severe pain and eventually stroke or organ damage.
Doctors have known for some time that bone marrow transplantation from a healthy donor can cure sickle cell disease. But few adults were transplanted because high-dose chemotherapy was needed to kill off the patients’ own blood-forming cells — and their entire immune system, to prevent rejection of the transplanted cells, leaving patients open to infection.
In the new procedure, patients receive immunosuppressive drugs just before the transplant, along with a very low dose of total body irradiation — a treatment much less harsh and with fewer potentially serious side effects than chemotherapy.
Next, donor cells from a healthy and tissue-matched sibling are transfused into the patient. Stem cells from the donor produce healthy new blood cells in the patient, eventually in sufficient quantity to eliminate symptoms. In many cases, sickle cells can no longer be detected. Patients must continue to take immunosuppressant drugs for at least a year.
In the reported trial, the researchers transplanted 13 patients, 17 to 40 years of age, with a stem cell preparation from the blood of a tissue-matched sibling. Healthy sibling donor-candidates and patients were tested for human leukocyte antigen, a set of markers found on cells in the body. Ten of these HLA markers must match between the donor and the recipient for the transplant to have the best chance of evading rejection.
In a further advance of the NIH procedure, physicians at UI Health successfully transplanted two patients with cells from siblings who matched for HLA but had a different blood type.
In all 13 patients, the transplanted cells successfully took up residence in the marrow and produced healthy red blood cells. One patient who failed to follow the post-transplant therapy regimen reverted to the original sickle cell condition.
None of the patients experienced graft-versus-host disease, a condition where immune cells originating from the donor attack the recipient’s body.
One year after transplantation, the 12 successfully transplanted patients had normal hemoglobin concentrations in their blood and better cardiopulmonary function. They reported less pain and improved health and vitality.
Four of the patients were able to stop post-transplantation immunotherapy without transplant rejection or other complications.
The Latest on: Sickle cell disease
via Google News
The Latest on: Sickle cell disease
- Novartis plans sickle cell awareness drive in Gulfon June 24, 2019 at 7:52 am
Novartis, a leading global pharmaceutical company, has announced that it will drive a series of educational roadshow meetings, which will coincide with World Sickle Cell Disease Month, to raise ... […]
- Cameroon: World Sickle Cell Day - CERAC Connects With Patientson June 24, 2019 at 4:42 am
The event was in line with activities to commemorate the World Sickle Cell Day which was celebrated on June 19. It was an occasion for CERAC members to better understand the genetic disease ... […]
- ‘Sickle Cell Disease not death sentence’ - Dr Amohon June 23, 2019 at 6:43 am
A medical officer at the Ghana Institute of Clinical Genetics (Sickle Cell Clinic), Dr Grace Amoh, has cautioned the general public against discrimination targeted at people with Sickle Cell Disease ... […]
- The debt the black race owes the sickle cell disease patienton June 22, 2019 at 11:32 pm
As we celebrate this year’s World Sickle Cell Day, Nigerians need to take a pause and appreciate what the disease means to us as nation, in particular and to the Black race, in general. I wonder how ... […]
- 'Sometimes I dey ask God why?' - Man wey born quadruplets wit sickle cellon June 22, 2019 at 5:16 pm
Wen pesin red blood cell no fit cari enough oxygen go round di whole bodi den dat pesin get sickle cell. Sickle cell anaemia na disease wey pesin fit inherit from im parents. Di pikin dia papa, Anaba ... […]
- New Sickle Cell Agent; Cosmetics and Kids: It's PodMed Double T!on June 22, 2019 at 11:12 am
This week's topics include a new agent for sickle cell, two ways to assess blood flow in the heart, the dangers of cosmetics for kids, and predicting who will develop dementia. Rick Lange, MD: ... […]
- Sickle cell treatment drug shows signs of working in clinical trial, UConn researchers sayon June 19, 2019 at 7:48 pm
HARTFORD, Conn. - An experimental drug developed by University of Connecticut medical researchers to treat sickle cell disease is "showing promise" in adult patients, according to a UConn Health news ... […]
- On World Sickle Cell Day, Medunik USA highlights the importance of early treatment of Sickle Cell Diseaseon June 19, 2019 at 3:59 pm
ROSEMONT, PA, June 19, 2019 /PRNewswire/ - This World Sickle Cell Day, Medunik USA, a company dedicated to improving the health and quality of life of Americans with rare diseases, highlights the ... […]
- Experimental drug shows promise against sickle cell diseaseon June 19, 2019 at 2:07 pm
An experimental drug for sickle cell disease reduced anemia and boosted the health of red blood cells in patients, according to a new study. Whether the drug, voxelotor, will have long-term health ... […]
- Three signs of real progress against sickle cell diseaseon June 19, 2019 at 7:47 am
A decade ago, the United Nations declared June 19 to be World Sickle Cell Awareness Day- and for good reason. This genetic condition warps round red blood cells into crescent-shaped ones that disrupt ... […]
via Bing News